Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 161
- Registration Number
- NCT05107115
- Locations
- 🇪🇸
Investigational Site Number :7240007, Pozuelo de Alarcón, Madrid, Spain
🇪🇸Investigational Site Number : 7240006, Pamplona, Navarra, Spain
🇪🇸Investigational Site Number :7240006, Pamplona, Navarra, Spain
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 196
- Registration Number
- NCT05104892
- Locations
- 🇪🇸
Investigational Site Number : 7240004, Santander, Cantabria, Spain
🇧🇬Investigational Site Number : 1000004, Kozloduy, Bulgaria
🇧🇬Investigational Site Number : 1000003, Sevlievo, Bulgaria
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 138
- Registration Number
- NCT05104567
- Locations
- 🇺🇸
Seattle Cancer Care Alliance Site Number : 8400009, Seattle, Washington, United States
🇳🇱Investigational Site Number : 5280001, Amsterdam, Netherlands
🇮🇹Investigational Site Number : 3800003, Milano, Italy
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1324
- Registration Number
- NCT05097287
- Locations
- 🇺🇸
Chandler Clinical Research Trials- Site Number : 8400147, Chandler, Arizona, United States
🇺🇸Pulmonary Associates - Deer Valley Office- Site Number : 8400155, Phoenix, Arizona, United States
🇺🇸Alpha Clinical Research Group - Dunwoody- Site Number : 8400116, Dunwoody, Georgia, United States
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 53
- Registration Number
- NCT05087212
- Locations
- 🇨🇳
Investigational Sites, China, China
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Conditions
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 169
- Registration Number
- NCT05086315
- Locations
- 🇺🇸
Seattle Childrens Hospital and Regional Medical Center Site Number : 8400014, Seattle, Washington, United States
🇺🇸Beth Israel Deaconess Medical Center-Site Number:8400004, Boston, Massachusetts, United States
🇺🇸The Ohio State University Comprehensive Cancer Center Site Number : 8400009, Columbus, Ohio, United States
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
- Conditions
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT05073783
- Locations
- 🇮🇹
Investigational Site Italy, Italy, Italy
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT05071053
- Locations
- 🇯🇵
Investigational Site Number : 3920004, Matsuyama-shi, Ehime, Japan
🇯🇵Investigational Site Number : 3920002, Kashiwa-shi, Chiba, Japan
🇹🇷Investigational Site Number : 7920003, Ankara, Turkey
A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
- Conditions
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 105
- Registration Number
- NCT05070663
- Locations
- 🇫🇷
Investigational site France, France, France
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 59
- Registration Number
- NCT05061420
- Locations
- 🇺🇸
City of Hope- Site Number : 8400007, Duarte, California, United States
🇺🇸University of Colorado- Site Number : 8400004, Aurora, Colorado, United States
🇺🇸University of Michigan- Site Number : 8400008, Ann Arbor, Michigan, United States